Proactive Investors - Run By Investors For Investors

Scancell presents Moditope data at prestigious cancer conference

Chief scientific officer Lindy Durrant presented two posters at the International Cancer Immunotherapy conference in Germany on Friday
conference hall
Data showed that Modi-1 had an anti-tumour effect on pancreatic, lung, ovarian and melanoma cancer models

Cancer drug developer Scancell Holdings PLC (LON:SCLP) presented the latest data from its Moditope platform at the International Cancer Immunotherapy conference in Germany – one of the most prestigious meetings in the industry’s calendar.

Moditope stimulates the production of killer CD4+ T cells that induce anti-tumour activity without toxicity.

The AIM-quoted firm’s chief scientific officer Lindy Durrant presented two posters at the conference on Friday.

LOOK: Take a look at the two posters

The data showed that Modi-1 – the lead product from the platform – induced strong anti-tumour immunity in pancreatic, lung, ovarian and melanoma cancer models with up to 100% survival.

“Our poster in collaboration with ISA Pharmaceuticals showed that Modi-1 conjugated to synthetic TLR1/2 agonists generated an anti-tumour response at up to 100-fold lower doses than Modi-1 alone and that these conjugated peptides induced a memory response against tumour re-challenge,” said Durrant.

“These results suggest that Modi-1 conjugated directly to TLR agonists could be a powerful new approach to the treatment of cancer.”

Shares rose 0.9% to 14.12p.

View full SCLP profile View Profile

Scancell Holdings Plc Timeline

January 31 2017

Related Articles

October 04 2017
US Food & Drug administration approval is yet to be granted but iclaprim, which has fast-track status, is closing in on the promised land.
Woman with tissue facing pollen
October 20 2017
Allergy, which saw its market share grow by a percentage point to 13%, is in a strong financial position, with £22.1mln in the bank
boy leaning against chain link fence
September 14 2017
We take a look back at the progress made by Summit in the five years since we first spoke to chief executive Glyn Edwards

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2017

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use